期刊
CANCER RESEARCH
卷 70, 期 24, 页码 10024-10027出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-10-3236
关键词
-
类别
资金
- European Molecular Biology Organization
- Fundacao para a Ciencia e Tecnologia [PTDC/BIA-BCM/71663/2006]
- Fundação para a Ciência e a Tecnologia [PTDC/BIA-BCM/71663/2006] Funding Source: FCT
Abundant interferon-gamma secretion, potent cytotoxicity, and major histocompatibility complex-independent targeting of a large spectrum of tumors make gamma delta T cells attractive mediators of cancer immunotherapy. However, a better understanding of the molecular mechanisms involved in tumor cell recognition and gamma delta T-cell activation is required to improve the limited success of gamma delta T-cell-mediated treatments. Here, we review key advances in basic knowledge made over the past 3 years, and summarize the results of gamma delta T-cell-based clinical trials concluded to date. We also highlight new research directions on the basis of the modulation of receptors that control the function of gamma delta T cells. Cancer Res; 70(24); 10024-7. (C) 2010 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据